SCHEMBL3330933

SCHEMBL3330933

NS(=O)(=O)c1ccc(C(=O)NCCN2CCOCC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 8/20 0.68
ALDH1A1 P00352 1/20 0.68
HTR1A P08908 1/20 0.68
MAOA P21397 1/20 0.68
MAOB P27338 1/20 0.68
KCNH2 Q12809 1/20 0.68
CA1 P00915 2/20 0.67
CA9 Q16790 2/20 0.67
CA12 O43570 1/20 0.67
HPGD P15428 1/20 0.65
POLB P06746 1/20 0.60
KDM4E B2RXH2 1/20 0.60
EPHX2 P34913 3/20 0.60
CA2 P00918 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3324927 0.93 TSHR (0.70) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL3325091 0.88 ALDH1A1 (0.64) ALDH1A1CA1CA9CA12HPGD
SCHEMBL3322319 0.87 CYP1A2 (0.67) ALDH1A1CA1CA9CA12HPGD
SCHEMBL3543817 0.84 CD274 (0.92) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL23742117 0.83 PHGDH (0.52) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL23742108 0.83 PHGDH (0.59) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL4488493 0.82 CD274 (0.77) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL6569882 0.82 CD274 (0.77) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL8404675 0.82 CD274 (0.71) CD274ALDH1A1HTR1AMAOAMAOB
SCHEMBL23742125 0.81 PHGDH (0.51) CD274ALDH1A1HTR1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
CN-101663267-A Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use UNIMED PHARMA SPOL SRO 2010-03-03 CN claimed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP claimed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO claimed
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP disclosed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed
CN-101663267-A Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use UNIMED PHARMA SPOL SRO 2010-03-03 CN disclosed
EP-2142499-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE Unimed Pharma, Spol. S R.O. (SK) 2010-01-13 EP disclosed
WO-2008130332-A1 SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 CD274 4872/4885ALDH1A1 967/4885HTR1A 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.